Overview
Palatin Technologies (NYSE Amex:PTN) is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin’s internally developed drug pipeline utilizes proprietary approaches to discover potent rigid conformers from flexible peptide starting points.
The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, inflammation-related diseases, ischemia and reperfusion injury and hemorrhagic shock.
The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension, asthma and other cardiovascular diseases.
Palatin has a collaboration with AstraZeneca (NYSE:AZN) on compounds that target melanocortin receptors for treatment of obesity, diabetes and related metabolic syndrome.
Product Portfolio
- Bremelanotide, a peptide melanocortin receptor agonist, for treatment of erectile dysfunction in patients non-responsive to current therapies.
- Bremelanotide for treatment of female sexual dysfunction.
- PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, acute severe asthma and refractory hypertension.
- PL-6983, a peptide melanocortin-4 receptor agonist, a back-up therapeutic for sexual dysfunction, including female sexual dysfunction.
- Research collaboration and global license with AstraZeneca on melanocortin receptor-based compounds for treating obesity and related metabolic syndrome.
|
